Functional restoration of a CFTR splicing mutation through RNA delivery of CRISPR adenine base editor.

CRISPR-Cas9 RNA delivery base editing cystic fibrosis gene editing gene therapy organoids primary bronchial epithelial cells

Journal

Molecular therapy : the journal of the American Society of Gene Therapy
ISSN: 1525-0024
Titre abrégé: Mol Ther
Pays: United States
ID NLM: 100890581

Informations de publication

Date de publication:
07 06 2023
Historique:
received: 04 11 2022
revised: 07 01 2023
accepted: 03 03 2023
pmc-release: 07 06 2024
medline: 12 6 2023
pubmed: 11 3 2023
entrez: 10 3 2023
Statut: ppublish

Résumé

Cystic fibrosis (CF) is a genetic disease caused by mutations in the CF transmembrane conductance regulator (CFTR) gene. The 2789+5G>A CFTR mutation is a quite frequent defect causing an aberrant splicing and a non-functional CFTR protein. Here we used a CRISPR adenine base editing (ABE) approach to correct the mutation in the absence of DNA double-strand breaks (DSB). To select the strategy, we developed a minigene cellular model reproducing the 2789+5G>A splicing defect. We obtained up to 70% editing in the minigene model by adapting the ABE to the PAM sequence optimal for targeting 2789+5G>A with a SpCas9-NG (NG-ABE). Nonetheless, the on-target base correction was accompanied by secondary (bystander) A-to-G conversions in nearby nucleotides, which affected the wild-type CFTR splicing. To decrease the bystander edits, we used a specific ABE (NG-ABEmax), which was delivered as mRNA. The NG-ABEmax RNA approach was validated in patient-derived rectal organoids and bronchial epithelial cells showing sufficient gene correction to recover the CFTR function. Finally, in-depth sequencing revealed high editing precision genome-wide and allele-specific correction. Here we report the development of a base editing strategy to precisely repair the 2789+5G>A mutation resulting in restoration of the CFTR function, while reducing bystander and off-target activities.

Identifiants

pubmed: 36895161
pii: S1525-0016(23)00125-9
doi: 10.1016/j.ymthe.2023.03.004
pmc: PMC10277887
pii:
doi:

Substances chimiques

Cystic Fibrosis Transmembrane Conductance Regulator 126880-72-6
RNA 63231-63-0
Adenine JAC85A2161
CFTR protein, human 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1647-1660

Informations de copyright

Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests A.C. is a co-founder and holds stocks of Alia Therapeutics, a genome editing company.

Références

STAR Protoc. 2020 Jun 03;1(1):100019
pubmed: 33111074
Eur Respir J. 2021 Jan 5;57(1):
pubmed: 32747394
Nat Med. 1995 Jan;1(1):39-46
pubmed: 7584951
Int J Mol Sci. 2021 May 17;22(10):
pubmed: 34067708
Thorax. 2017 Feb;72(2):137-147
pubmed: 27852956
Nat Genet. 1995 Feb;9(2):126-31
pubmed: 7719338
Front Pharmacol. 2020 Feb 21;10:1662
pubmed: 32153386
Hum Mutat. 2014 Oct;35(10):1249-59
pubmed: 25066652
Sci Rep. 2016 Aug 25;6:32230
pubmed: 27557525
Nat Commun. 2019 Mar 8;10(1):1136
pubmed: 30850590
Cell Stem Cell. 2013 Dec 5;13(6):653-8
pubmed: 24315439
Cell Rep. 2015 Sep 1;12(9):1385-90
pubmed: 26299960
Genome Biol. 2019 Jan 17;20(1):14
pubmed: 30654827
Eur J Hum Genet. 2014 Jun;22(6):784-91
pubmed: 24129438
CRISPR J. 2021 Feb;4(1):120-131
pubmed: 33571043
Biomaterials. 2018 Feb;156:172-193
pubmed: 29197748
J Comput Biol. 2004;11(2-3):377-94
pubmed: 15285897
Nat Biotechnol. 2015 Feb;33(2):187-197
pubmed: 25513782
Am J Physiol Lung Cell Mol Physiol. 2005 Dec;289(6):L1123-30
pubmed: 16085675
Cells. 2020 Sep 13;9(9):
pubmed: 32933106
Methods. 2005 Dec;37(4):331-40
pubmed: 16314262
Bioinformatics. 2014 May 15;30(10):1473-5
pubmed: 24463181
Lancet Respir Med. 2016 Feb;4(2):107-15
pubmed: 26803277
Genome Res. 2014 Jun;24(6):1012-9
pubmed: 24696461
Cells. 2020 Mar 19;9(3):
pubmed: 32204475
Nat Biotechnol. 2018 Sep;36(8):765-771
pubmed: 30010673
Prog Mol Biol Transl Sci. 2021;182:185-224
pubmed: 34175042
Cell Stem Cell. 2016 Aug 4;19(2):217-231
pubmed: 27320041
Nat Biotechnol. 2018 Oct;36(9):843-846
pubmed: 29813047
Lancet Respir Med. 2019 Apr;7(4):325-335
pubmed: 30686767
Nucleic Acids Res. 2022 Apr 8;50(6):3456-3474
pubmed: 35244719
Nat Med. 2013 Jul;19(7):939-45
pubmed: 23727931
Adv Drug Deliv Rev. 2021 Jan;168:3-29
pubmed: 31759123
Nature. 2019 Dec;576(7785):149-157
pubmed: 31634902
Nat Commun. 2020 Apr 24;11(1):1979
pubmed: 32332735
Nature. 2017 Nov 23;551(7681):464-471
pubmed: 29160308
Biomater Sci. 2022 Mar 2;10(5):1166-1192
pubmed: 35103261
J Biotechnol. 2015 Aug 20;208:44-53
pubmed: 26003884
Lancet. 2021 Jun 5;397(10290):2195-2211
pubmed: 34090606
Mol Ther Nucleic Acids. 2019 Jun 7;16:73-81
pubmed: 30852378
J Cyst Fibros. 2020 Jan;19(1):68-79
pubmed: 31196670
J Clin Invest. 1996 Mar 15;97(6):1504-11
pubmed: 8617884
Nat Biotechnol. 2019 Mar;37(3):224-226
pubmed: 30809026
Nature. 2016 Apr 20;533(7603):420-4
pubmed: 27096365
PLoS One. 2017 Sep 1;12(9):e0184009
pubmed: 28863137
Nat Biotechnol. 2020 Jul;38(7):883-891
pubmed: 32433547
Genes (Basel). 2019 May 21;10(5):
pubmed: 31117296
CRISPR J. 2018 Jun;1:239-250
pubmed: 31021262
Cell Stem Cell. 2020 Feb 6;26(2):161-171.e4
pubmed: 31839569
Am J Respir Cell Mol Biol. 2009 Jun;40(6):717-23
pubmed: 19011164
Cell Stem Cell. 2020 Apr 2;26(4):503-510.e7
pubmed: 32084388
Nat Rev Dis Primers. 2015 May 14;1:15010
pubmed: 27189798
Nucleic Acids Res. 2021 Oct 11;49(18):10558-10572
pubmed: 34520545
Nat Biotechnol. 2020 Jul;38(7):892-900
pubmed: 32284586
ERJ Open Res. 2022 Apr 19;8(2):
pubmed: 35449760
Int J Mol Sci. 2020 May 30;21(11):
pubmed: 32486152
PLoS Biol. 2009 Jul;7(7):e1000155
pubmed: 19621064
Nature. 2018 Aug;560(7717):E8-E9
pubmed: 30089922
Cell. 1993 Oct 22;75(2):207-16
pubmed: 7691415
Eur Respir J. 2005 Mar;25(3):468-73
pubmed: 15738290
J Physiol. 2012 Dec 1;590(23):6141-55
pubmed: 22988141
Nat Genet. 2021 Jun;53(6):895-905
pubmed: 33846636
Mol Ther. 2020 Jul 8;28(7):1684-1695
pubmed: 32402246
Hum Mol Genet. 2019 Oct 1;28(R1):R88-R94
pubmed: 31332440
Nat Rev Drug Discov. 2022 Aug;21(8):545-547
pubmed: 35831515
Nat Commun. 2017 May 22;8:15334
pubmed: 28530235
Nat Commun. 2019 Aug 7;10(1):3556
pubmed: 31391465
ERJ Open Res. 2019 Jun 17;5(2):
pubmed: 31218221

Auteurs

Simone Amistadi (S)

University of Trento, Department of Computational, Cellular and Integrative Biology, Laboratory of Molecular Virology, 38123 Trento, Italy.

Giulia Maule (G)

University of Trento, Department of Computational, Cellular and Integrative Biology, Laboratory of Molecular Virology, 38123 Trento, Italy. Electronic address: giulia.maule@unitn.it.

Matteo Ciciani (M)

University of Trento, Department of Computational, Cellular and Integrative Biology, Laboratory of Molecular Virology, 38123 Trento, Italy.

Marjolein M Ensinck (MM)

KU Leuven, Department of Pharmaceutical and Pharmacological Sciences, Laboratory for Molecular Virology and Gene Therapy, 3000 Leuven, Belgium.

Liesbeth De Keersmaecker (L)

KU Leuven, Department of Pharmaceutical and Pharmacological Sciences, Laboratory for Molecular Virology and Gene Therapy, 3000 Leuven, Belgium.

Anabela S Ramalho (AS)

CF Research Lab, Woman and Child Unit, Department of Development and Regeneration, KU Leuven, 3000 Leuven, Belgium.

Daniela Guidone (D)

Telethon Institute of Genetics and Medicine, 80078 Pozzuoli, Italy.

Martina Buccirossi (M)

Telethon Institute of Genetics and Medicine, 80078 Pozzuoli, Italy.

Luis J V Galietta (LJV)

Telethon Institute of Genetics and Medicine, 80078 Pozzuoli, Italy; Department of Translational Medical Sciences, University of Napoli "Federico II," 80138 Napoli, Italy.

Marianne S Carlon (MS)

KU Leuven, Department of Pharmaceutical and Pharmacological Sciences, Laboratory for Molecular Virology and Gene Therapy, 3000 Leuven, Belgium; KU Leuven, Department of Chronic Diseases and Metabolism, BREATHE Laboratory, 3000 Leuven, Belgium.

Anna Cereseto (A)

University of Trento, Department of Computational, Cellular and Integrative Biology, Laboratory of Molecular Virology, 38123 Trento, Italy. Electronic address: anna.cereseto@unitn.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH